Advertisement

Topics

Axovant gains worldwide license to Oxford BioMedica's OXB102 gene therapy candidate for PD

15:40 EDT 8 Jun 2018 | Elsevier Business Intelligence

Axovant Sciences Ltd. licensed exclusive worldwide rights to Oxford BioMedica PLC's OXB102, an in vivo lentiviral vector gene...

Original Article: Axovant gains worldwide license to Oxford BioMedica's OXB102 gene therapy candidate for PD

NEXT ARTICLE

More From BioPortfolio on "Axovant gains worldwide license to Oxford BioMedica's OXB102 gene therapy candidate for PD"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...